Development of HTLV-1 peptide vaccine for treatment and prevention of ATL

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K09481
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Hematology
• Research Institution: Kagoshima University
• Principal Investigator: Arima Naomichi 鹿児島大学, 医歯学総合研究科, 客員研究員 (30175997)
• Co-Investigator(Kenkyū-buntansha): 小迫 知弘 福岡大学, 薬学部, 准教授 (40398300) ; 久保田 龍二 鹿児島大学, 医歯学域医学系, 教授 (70336337) ; 吉満 誠 鹿児島大学, 医歯学域医学系, 准教授 (70404530)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: HTLV-1 / ワクチン

Outline of Final Research Achievements

To see if HTLV-1 related protein can be the candidate for cytotoxic T lymphocyte (CTL) -type vaccination target for prevention and treatment of adult T-cell leukemia/lymphoma (ATL), we chose HBZ, constitutively expressing HTLV-1 related protein in ATL, as CTL-type vaccination target. Although we detect HBZ-specific CTL in HAM/TSP patients, another HTLV-1 virus assosiated neurological disorder, we were not able to detect HBZ-specific CTL in ATL patients, who were postive for HTLV-1 Tax-CTL . We were not able to detect HBZ-specific CTL even in ATL patients after allogeneic hematopoietic stem cell transplantation. Thus, we concluded that HBZ protein has too weak immunogenecity to elicit vaccination effect for prevention and treatment of ATL.

Free Research Field

HTLV-1